Correlation between GST gene polymorphism and concentration of azathioprine active metabolite 6-TGN in patients with inflammatory bowel disease
10.12092/j.issn.1009-2501.2025.10.010
- VernacularTitle:炎症性肠病患者GST基因多态性与硫唑嘌呤活性代谢物6-TGN浓度水平相关性研究
- Author:
Jiashan DONG
1
;
Jiarui CHEN
;
Dayong ZENG
;
Yiwei LIU
;
Jianwen XU
;
Rongfang LIN
Author Information
1. 厦门医学院附属第二医院药学部,厦门 361021,福建
- Publication Type:Journal Article
- Keywords:
inflammatory bowel disease;
GST ge-netic polymorphism;
azathioprine;
6-TGN concen-tration
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(10):1383-1390
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To investigate the effects of glutathione-S-transferase(GST)gene polymorphism on the concentration of 6-thioguanine nucleotides(6-TGN),an active metabolite of azathioprine(AZA),in patients with inflammatory bowel disease(IBD),in order to provide reference for the optimization of AZA treatment in patients.METHODS:The clini-cal data of patients with IBD treated by AZA were collected prospectively,the genotypes of GST-A1,GST-M1,GST-P1 and GST-T1 were detected by tar-geted sequencing of multiplex PCR combined with high-throughput sequencing technology before ad-ministration,and the steady-state trough concen-trations of 6-TGN in patients' red blood cells were determined by HPLC.Statistical analysis was carried out by SPSS 26.0 software.RESULTS:A total of 90 patients were included in this study.The alleles fre-quencies of GST-A1,GST-M1,GST-P1 and GST-T1 were consistent with Hardy-Weinberg equilibrium law.Logistic regression analysis showed that carry-ing GST-A1 mutant gene was an independent risk factor for the increase of trough concentration of 6-TGN(low concentration OR=17.50,P=0.030;high concentration OR=3.60,P=0.033),while the gene polymorphism of GST-M1,GST-P1,GST-T1 had no significant correlation with the concentration of 6-TGN(P＞0.05).CONCLUSION:The gene polymor-phism of GST-A1 may affect the concentration of 6-TGN,an active metabolite of AZA,and detection of GST-A1 genotype before AZA treatment will contrib-ute to clinical individualized medication.
